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Epigenetic modifications are stable alterations in gene expression that do not involve
mutations of the genetic sequence itself. It has become increasingly clear that
epigenetic factors contribute to the outcome of chronic hepatitis B virus (HBV)
infection by affecting cellular and virion gene expression, viral replication and the
development of hepatocellular carcinoma. HBV persists in the nucleus of infected
hepatocytes as a stable non-integrated covalently closed circular DNA (cccDNA)
which functions as a minichromosome. There are two major forms of HBV epigenetic
regulation: posttranslational modification of histone proteins associated with the
cccDNA minichromosome and DNA methylation of viral and host genomes. This review
explores how HBV can interphase with host epigenetic regulation in order to evade
host defences and to promote its own survival and persistence. We focus on the effect
of cccDNA bound-histone modifications and the methylation status of HBV DNA in
regulating viral replication. Investigation of HBV epigenetic control has important clinical
correlates with regards to the development of potential therapeutic regimens that will
successfully eradicate HBV infection and deal with HBV reactivation in those undergoing
treatment with demethylating agents.
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INTRODUCTION
Hepatitis B virus (HBV) is a highly transmissible pathogen infecting humans for more than
1500 years (Zhou and Holmes, 2007). Despite the availability of a prophylactic vaccine for more
than three decades now, HBV continues to pose one of the most prevalent health problems with
about 240 million people worldwide chronically infected and accounting for over 600,000 deaths
per year (WHO, 2015). Current therapeutic regimens include pegylated-IFN-α (PegIFN-α) and
nucleos(t)ide analogs (NAs). Both types of antiviral treatment are not capable of eliminating the
virus and do not establish long-term control of infection after treatment withdrawal in the majority
of patients.
HBV is the prototype of the hepadnaviridae family and has evolved a distinctive and successful
replication strategy, which allows its indeﬁnite persistence in the liver of the infected host. Upon
infection of the hepatocyte, the HBV genome translocates to the nucleus, where its relaxed circular,
partially double stranded DNA is converted into a covalently closed circular DNA (cccDNA)
molecule. The cccDNA is the template for the synthesis of six co-terminal mRNA transcripts
(Tuttleman et al., 1986; Seeger andMason, 2000). One of the transcripts, termed pre-genomic RNA
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(pgRNA), is the template for genome replication and encodes for
the core and polymerase proteins. Translation of the transcripts
occurs in the cytoplasm and the encapsidation of the pgRNA
into core particles follows (Levrero et al., 2009). Inside the core
particle, the viral polymerase directs the synthesis of the minus
DNA strand of the genome by reverse transcription of the pgRNA
template, which then serves as the template for plus DNA strand
synthesis. Mature core particles containing DNA genomes are
then enveloped and released or cycled back to the nucleus to
replenish the cccDNA pool (Tuttleman et al., 1986). Persistent
infection of HBV relies on the stable maintenance and proper
function of the cccDNA pool in the nucleus of the infected
hepatocytes. Variable levels of cccDNA can be found in diﬀerent
phases of the natural history of chronic HBV patients. In HBeAg-
negative patients or inactive carriers, cccDNA transcription is
about 10-fold lower than that in HBeAg-positive patients, while
cccDNA levels can be detected in cases with absent or very
low viral replication (Werle-Lapostolle et al., 2004; Liu et al.,
2013).
Amongst the smallest of all known virus genomes, the
3.2 kb HBV genome contains four partially overlapping open
reading frames (ORFs). HBV transcription is regulated by
its four promoters and by cis-acting viral elements including
two enhancers (enhancer I and enhancer II) and a negative
regulatory region that depend on host transcription factors for
their function (Moolla et al., 2002). Additionally, a number of
epigenetic modiﬁcations have been identiﬁed which regulate viral
replication and viral gene expression. Non-integrated nuclear
HBV DNA associates with histones combined with HBcAg to
form stable cccDNA minichromosomes (Bock et al., 2001).
Chromatin condensation of cccDNA is a critical step for the
regulation of viral gene expression because it determines the
accessibility of DNA to the regulatory transcription factors.
The acetylation status of cccDNA bound histones controls
HBV replication in a fashion identical to that seen in human
genes; hypoacetylation correlates with low viral replication and
hyperacetylation leads to increased HBV replication (Pollicino
et al., 2006). In addition, both viral and host DNA are known to
be targets for methylation in chronic HBV infection suggesting
dual eﬀects of methylation as potentially both protective and
harmful for the host (Guo et al., 2009; Vivekanandan et al.,
2009; Kaur et al., 2010). This review will provide an overview of
how epigenetic factors, including genomic DNAmethylation and
histone modiﬁcations, contribute in HBV persistence and HBV-
induced cancer as well as their possible therapeutic implications
in chronic HBV infection.
CHROMATIN ORGANIZATION AND
EPIGENETIC MODIFICATIONS
A number of epigenetic modiﬁcations have been recently
identiﬁed that control viral replication in chronic HBV infection.
Chromatin condensation of cccDNA is a critical step in the
regulation of viral gene expression because it determines the
accessibility of DNA to the regulatory transcription factors. It
can be modulated through a variety of mechanisms, including
posttranslational covalent modiﬁcations of histone tails, ATP-
dependent chromatin remodeling events and recruitment of
repressor factors on methylated DNA. Methylation is another
common cellular defence mechanism in mammalian cells
known to silence invading foreign DNA and viral genomes.
It permits binding of protein complexes with chromatin-
modulating properties and strictly depends on where the methyl
group is located. Many host and viral promoters are enriched
for CpG dinucleotides and methylation of cytidine leads to
gene inactivation. Generally, DNA methylation at the promoter
region leads to repression of gene expression, because the 5-
methyl-cytosine interferes with the recognition and binding of
transcriptional factors, to diminish mRNA transcription (Bird,
2002).
HISTONE ACETYLATION
Histone modiﬁcations are all reversible and mainly localized
at the amino-terminal histone tails. They include acetylation,
methylation, phosphorylation, sumoylation, ubiquitination,
ADP-ribosylation, deamination, and the non-covalent proline
isomerization (histone H3) (Liu et al., 2012). To further increase
the complexity, many of these modiﬁcations occur multiple
times at the same residue of a histone tail and they inﬂuence gene
expression patterns by two diﬀerent mechanisms: (1) histone
acetylation, which alters chromatin packaging allowing access
to transcriptional machinery; and (2) by histone methylation,
which generates interactions with chromatin-associated proteins.
Several enzymes catalyze these processes, including histone
acetyltransferases (HATs), histone deacetylases (HDACs),
histone methylatransfecrases (HMTs), and histone demethylases
(HDMTs). HATs and HDACs regulate transcription by selectively
acetylating or deacetylating the ε-amino group of lysine residues
in histone tails. Histone acetylation induced by HATs promotes
chromatin opening and associates with gene transcription while
histone hypoacetylation induced by HDACs diminishes the
accessibility of the nucleosomal DNA to transcription factors
and is associated with gene silencing (Berger et al., 2009).
DNA METHYLATION
DNAmethylation occurs at the 5-methyl cytosine predominantly
in the context of CpG dinucleotides with S-adenosyl methionine
as the methyl donor (Bird, 2002). CpG dinucleotides are
often found accumulated in conserved regulatory regions
(CpG islands) demonstrating their functional importance. The
mammalian DNA methylation machinery consists of the DNA
methyltransferases (DNMTs), which are responsible for the
enzymatic addition of methyl groups, and the methyl-CpG-
binding proteins (MBPs), which identify the methylation
pattern (Egger et al., 2004). The DNMT family includes
DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3A.
DNMT1 maintains the methylation pattern during cell division
and methylates hemimethylated CpG islands. DNMT3A and
DNMT3B can methylate unmethylated and hemimethylated
Frontiers in Microbiology | www.frontiersin.org 2 January 2016 | Volume 6 | Article 1491
Koumbi and Karayiannis Epigenetic Control of Hepatitis B Virus
CpG islands while DNMT2 lacks methyltransferase capabilities
but plays a role in methylation of structural RNA (Jurkowska and
Jeltsch, 2010).
DNA hypomethylation signiﬁes one of the major DNA
methylation states and refers to a relative situation that
indicates a decrease from the “normal” methylation level.
Hypomethylation in transcriptional regulatory regions generally
induces gene silencing, either directly, by blocking the binding of
transcription factors to their recognition sequences or indirectly,
by preventing transcription factors from accessing their target
sites through the attachment of MBPs. In turn, methyl-CpG
binding domain proteins can recruit histone-modifying and
chromatin remodeling complexes, such as HMTs and HDACs, to
methylated sites resulting in histone methylation of certain amino
acids in a histone (Lopez-Serra and Esteller, 2008). HMTs catalyze
the transfer of methyl groups to histones and thus they regulate
DNA methylation through chromatin-dependent transcription
control. Histone methylation can cause transcription repression
or activation depending on the target sites and thus serves in both
epigenetic gene activation and silencing.
ACETYLATION OF THE cccDNA
MINICHROMOSOME
Hepatitis B virus cccDNA is formed by histone and non-histone
proteins. Hypoacetylation of the cccDNA-associated H3 and H4
histones and the recruitment of the cellular acetyltransferases
p300/CREB-binding protein (CBP) and HDAC1 onto cccDNA
have been associated with low HBV replication both in vivo
and in vitro (Pollicino et al., 2006). In addition, the presence
of class I/II histone deacetylase inhibitors (valproic acid and
trichostatin (TSA)) has been shown to induce an increase in HBV
replication and the upregulation of cccDNA-bound H4 histones
in a HepG2 cell based model (Pollicino et al., 2006) (Figure 1;
Table 1). However, another study that used duck hepatitis B virus
(DHBV) in vitro showed that a number of HDAC inhibitors,
including TSA, suppressed cccDNA transcription and reduced
HBV replication in a dose-response manner (Yan et al., 2012;
Liu et al., 2013). Therefore it can be assumed that a cellular
function sensitive to HDAC inhibitors is required for HBV RNA
transcription.
HBV replication is known to be strongly inhibited by
the administration of IFN-α, a type I IFN, that engages the
IFN-α/β receptor complex to modulate the transcription of
the IFN-stimulating genes (ISGs) via the Jak/Stat signaling
pathway. Recently it has been shown in HBV-replicating cells
and in HBV-infected chimeric uPA/SCID mice that IFN-α
inhibits cccDNA-driven transcription by targeting the epigenetic
control of cccDNA with the involvement of the chromatin
remodeling Polycomb Repressive Complex 2 (Belloni et al.,
2012). In response to IFN-α, cccDNA-bound histones become
hypoacetylated and both components of the transcriptional
repressor complex, YY1 and Ezh2, and the HDAC1 and hSirt are
actively recruited onto cccDNA (Belloni et al., 2012). However,
another study, using a DHBV cell based model demonstrated
FIGURE 1 | Schematic representation of the chromatin changes on cccDNA in relation to viral replication. The acetylation status of cccDNA-bound
histones and the recruitment of chromatin modifying enzymes onto cccDNA change in response to IFNα treatment and HBx status. In high viral replication of the wild
type virus or in the absence of IFNα treatment, cccDNA-bound histones are hyperacetylated, cccDNA-associated chromatin is in an open configuration and pgRNA
is actively transcribed. In cells replicating an HBx mutant and in IFNα-treated cells, cccDNA-bound histones are hypoacetylated, the recruitment of the p300
acetyltransferase is severely impaired, whereas the recruitment of the histone deacetylases (HDACs) hSirt1 and HDAC1 as well as the polycomb protein enhancer of
zeste homolog 2 (Ezh2) is increased. In the absence of HBx, hypoacetylation is accompanied by the recruitment of heterochromatin protein 1 factors (HP1) and SET
domain, bifurcated 1(SETDB1). Modified from Belloni et al. (2009).
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TABLE 1 | An outline of the main research findings on the (A) methylation
and (B) acetylation mechanisms involved in HBV infection.
Reference
(A) Findings on HBV DNA methylation
Methylation of integrated HBV DNA. Chen et al., 1988
HBx induces DNMT activity and
hypermethylation of tumor suppressor gene
promoters via DNMT3A1 and DNMT3A2
methylation.
Park et al., 2007
Island II methylation correlates with low or no
HBsAg production. cccDNA methylation
correlates with viral gene expression levels.
Vivekanandan et al., 2008a
Methylation of integrated and non-integrated
liver HBV DNA in islands I (60%) and II (50%).
Unmethylated serum HBV DNA.
Vivekanandan et al., 2008b
cccDNA methylation correlates with
HBeAg-positivity in CHB patients and impairs
virion productivity.
Guo et al., 2009
HBV DNA is unmethylated in early
carcinogenesis and highly methylated in cancer.
Methylation of HBcAg and HBsAg genes
inhibits their expression.
Fernandez et al., 2009
HBx recruits DNMT3A and induces the
methylation and transcriptional silencing of IL-4
receptor and metallothionein-1F.
Zheng et al., 2009
HBx expression correlates with DNMT1 and
DNMT3A and hypermethylation of the p16INK4A
promoter in CHB patients.
Zhu et al., 2010
cccDNA methylation is associated with HBV
viremia and aging in cirrhotic CHB patients.
Kim et al., 2011
HBV DNA methylation correlates with
decreased viral replication and gene
expression.
Vivekanandan et al., 2009
Increased expression of DNMT3
down-regulates viral protein and pgRNA
production.
HBV induces DNMT overexpression and
correlates with methylation of host CpG islands.
Vivekanandan et al., 2010
HBV DNA methylation in CHB implicates island
I in14%, island II 0.6% and island III 3.7% of
cases.
HBV DNA is unmethylated in CHB and highly
methylated in HBV-related cancer.
Kaur et al., 2010
HBV DNA is unmethylated in occult HBV.
CpG island I methylation correlates with HCC
development.
HBV CpG island distribution differs between
HBV genotypes.
Zhang et al., 2013
HBx induces the hypermethylation of the uPA
promoter (via the recruitment of DNMT3A2)
leading to liver regeneration impairment.
Park et al., 2013
(Continued)
that IFN-α reduced the acetylation of cccDNA-bound H3K9 and
H3K27 histone residues but failed to induce cccDNA-bound
H3K9me3 and H3K27me2 demethylases (Liu et al., 2013). In
addition, HDAC inhibitors blocked DHBV cccDNA transcription
but did not aﬀect the long-lasting IFNα-induced suppression of
cccDNA transcription (Liu et al., 2013). It is possible that the
reduced acetylation of H3K9 and H3K27 by IFN-α is catalyzed
by HDACs that are not susceptible to the HDAC inhibitors
TABLE 1 | Continued
Reference
(B) Findings on the acetylation of the cccDNA minichromosome
Low HBV replication correlates with cccDNA
hypoacetylation and the recruitment of
p300/CBP and HDAC1.
Histone deacetylase inhibitors restore HBV
replication.
Pollicino et al., 2006
HBx recruitment onto cccDNA correlates with
HBV replication and acetyltransferase
upregulation.
In the absence of HBx, HBV decreased
replication correlates with cccDNA
hypoacetylation; p300 inhibition; reduced
pgRNA, and deacetylase increase.
Belloni et al., 2009
IFN-α treatment reduces DHBV acetylation of
cccDNA-bound H3K9 and H3K27 histones but
has no effect on cccDNA-bound H3K9me3 and
H3K27me2 demethylases.
HDAC inhibitors block DHBV cccDNA
transcription but not the long-lasting
IFN-α-induced suppression of cccDNA.
Liu et al., 2013
IFN-α inhibits viral transcription by cccDNA
hypoacetylation through active recruitment onto
cccDNA of HDAC and of the transcriptional
repressor complex.
Belloni et al., 2012
IL6 induces cccDNA hypoacetylation and
silencing by reducing the binding of
transcription factors (HNF1α, HNF4α, and
STAT3) onto cccDNA.
Palumbo et al., 2015
HBx recruitment onto cccDNA activates HBV
transcription by counteracting
chromatin-mediated transcriptional repression
established by SETDB1, HP1 and H3K9me3.
Riviere et al., 2015
IFN-α represses HBV by reducing active PTMs
in cccDNA and that this effect can be
recapitulated with the C646 agent (inhibits
p300/CBP)
The repressive mark H3K27me3 is
underrepresented in cccDNA
Tropberger et al., 2015
DNMT, DNA methyltransferase; uPA, urokinase-type plasminogen activator; CBP,
CREB-binding protein; pgRNA, pregenomic RNA; cccDNA, covalently closed
circular DNA; DHBV, duck hepatitis B virus; HDAC, histone deacetylase; HNF1α,
hepatocyte nuclear factor 1α; HNF4α, hepatocyte nuclear factor 4α; SETDB1,
SET domain, bifurcated 1; HP1, heterochromatin protein 1 factors; and PTM,
posttranslational covalent modifications.
used in the DHBV study or that this reduction is due to the
disruption of a dynamic acetylation and deacetylation of histone
H3 through preventing the recruitment of HATs onto DHBV
cccDNA (Figure 1) (Liu et al., 2013). Interestingly, a recent
study demonstrated that IFN-α represses HBV by reducing active
PTMs on the cccDNA minichromosome and that this eﬀect can
be recapitulated with treatment with a small epigenetic agent,
C646, which speciﬁcally inhibits p300/CBP HATs (Tropberger
et al., 2015). Nevertheless, these ﬁndings suggest that IFN-α
induces a persistent condition of “active epigenetic control” of
cccDNA, involving all HBV transcripts that may contribute to
the persistent, yet reversible, “oﬀ-therapy” inhibition of HBV
replication. Contrary to IFN-α, treatment with IL6, another
activator of the intracellular Jak/Stat signaling pathway, reduces
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cccDNA acetylation and transcription but without aﬀecting
cccDNA chromatinization (Palumbo et al., 2015). Instead IL6
has been shown to inhibit cccDNA transcription by reducing the
binding of essential transcription factors HNF1α and HNF4α to
cccDNA and by redistributing STAT3 binding from the cccDNA
to IL6 cellular target genes (Palumbo et al., 2015).
HBx, a pleiotropic regulatory protein, acts as a promiscuous
transactivator of viral and cellular promoters and is found in the
cytoplasm and the nucleus of infected hepatocytes (Cougot et al.,
2007). HBx activates the transcription of host genes by interacting
directly with nuclear transcription factors or by activating various
signal transduction pathways in the cytoplasm. In addition to
its trans- and cis-activating roles, HBx protein has been proven
to be a potent epigenetic modifying factor in liver tissue. It has
been reported to modify chromatin dynamics in vivo by favoring
the transcription of a number of CREB-regulated genes via the
recruitment of the cellular acetyltransferases CBP and p300 to
their promoters (Cougot et al., 2007). HBx is reported to activate
HBV transcription by its recruitment onto cccDNA, through
recruitment of PCAF/GCN5, p300 and CBP acetyltransferases
onto cccDNA and through the inhibition of cellular factors
involved in chromatin regulation, such as PP1/HDAC1 complex
(Belloni et al., 2009; Riviere et al., 2015). On the contrary, in
the absence of HBx, HBV replication was suppressed and this
decrease correlated with the rapid hypoacetylation of cccDNA-
bound histones, the severe impairment of the p300 recruitment
and the reduced transcription of pgRNA from cccDNA, whereas
the recruitment of the HDACs hSirt1 and HDAC1 preceded
(Belloni et al., 2009). Notably, the IFN-α-induced cccDNA
repression through hSirt andHDAC1 up-regulation was reported
to be HBx independent (Belloni et al., 2012). A recent study
showed that in the absence of HBx, HBV silencing associated not
only with the deacetylation of histones but also with deposition
of repressive chromatin markers (H3K9me2 and H3K9me3),
the recruitment of heterochromatin protein 1 factors and the
recruitment of SET domain, bifurcated 1 (SETDB1) histone
methylatransferases that methylate H3K9 histone (Riviere et al.,
2015). Interestingly, SETDB1 has been shown to be an oncogene
and is signiﬁcantly associated with HCC disease progression
(Wong et al., 2015).
HBV DNA METHYLATION
In chronic HBV infection, viral DNA methylation has been
identiﬁed as a novel host defence mechanism, leading to
the downregulation of viral gene expression. However, the
association of HBV DNA methylation with the methylation of
host genes and the development of cancer imply a harmful eﬀect
on the host. HBV DNA can be methylated in human tissues
in both non-integrated forms (Vivekanandan et al., 2008b) and
following integration into the human tissue (Chen et al., 1988).
NON-INTEGRATED HBV GENOME
The HBV genome contains three predicted CpG islands
overlapping the start site of the S gene (island I); the region
encompassing enhancer I, the X gene promoter (island II); and
the region harboring the Sp1 promoter and the start codon of
the P gene (island III) (Figure 2) (Vivekanandan et al., 2008b;
Kaur et al., 2010). Kaur and his group in France reported a
14% methylation frequency in CpG island I, 0.6% methylation
in island II and 3.7% in island III in CHB patients (Kaur et al.,
2010). However, a computation study, reported that 50% of the
HBV sequences examined lacked island I, while islands II and III
were more conserved across genotypes (Zhang et al., 2013). The
authors argued that conﬂicting results between HBVmethylation
studies are due to diﬀerent HBV genotypes examined. High viral
mutation frequencies and high viral replication rates in CHB
infection can lead to a great degree of variability in CpG island
distribution throughout the viral genome (Zhang et al., 2013).
The methylation status of island II has been greatly associated
with reduced viral gene expression and replication as compared
with islands I and III (Table 1). High methylation levels on
island II were correlated with absent or low levels of HBsAg
production while hypermethylation patterns were also reported
in occult HBV cases and in HBsAg negative patients with HCC
(Vivekanandan et al., 2008b; Kaur et al., 2010). In addition
to transcriptionally regulatory genes, island II overlaps with
the transcriptional control region of HBV cccDNA. Findings
on the role of cccDNA methylation in HBV replication are
controversial. Studies from several groups in Asia reported
cccDNA methylation in human tissue and further showed that
it impairs the cccDNA’s replication capability and viral gene
expression (Guo et al., 2009; Vivekanandan et al., 2009; Kim
et al., 2011). However, the study of Guo et al. (2009) included
patients with a serum HBV DNA load of more than 103
copies/ml, whilst Vivekandam and his group included liver
cancer tissue; neither study made any correlation between
cccDNA methylation and viral load, while both studies did
not mention the presence of ﬁbrosis. A third study from Kaur
et al. (2010) included a small number of liver cirrhosis patients
(n = 12), in which cccDNA methylation was associated with
serum viremia. Contrary to these reports, a study from France,
demonstrated that the HBV genome, including island II, is
rarely targeted for DNA methylation in liver samples from CHB
patients (Kaur et al., 2010). A Korean study of cirrhotic patients,
reported that increased cccDNA methylation is associated with
older age (Kim et al., 2011). The authors postulated that
considering that perinatal transmission is the main mode of
HBV infection and the stability of cccDNA, it is possible that
methylated cccDNA may be passed to daughter cells after mitotic
division, and additional methylation of replenished cccDNA
may increase methylation frequency of the cccDNA population
in chronic HBV infection (Kim et al., 2011). Furthermore,
CpG island II is in close proximity to the core gene promoter
and enhancer II and its hypermethylation can suppress Pre-
C/C gene transcription, and consequently HBeAg expression
in CHB patients (Guo et al., 2009). HBeAg seroconversion
is attributed to hotspot mutations in the precore/BCP region
(A1762T/G1764A, G1896A, G1899A) that abrogate or reduce
HBeAg secretion (Jammeh et al., 2008). However, in the absence
of these mutations cccDNA methylation density was reported to
be signiﬁcantly higher in liver cells of HBeAg(−) patients than in
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FIGURE 2 | Schematic representation of the open reading frames (ORFs) of pre-core/core, polymerase (P), surface (S), and X proteins with the
genome in open configuration; the four promoters, cp, sp1, sp2, and xp, as well as the main regulatory elements, enhancers I and II (Enh I and Enh
II), are indicated. The positions of the three predicted CpG islands within the HBV genome are shown as shaded boxes. Nucleotide numbering is based on the
EcoRI restriction site as position 1.
HBeAg(+) patients (Guo et al., 2009). Interestingly, within the
same HBeAg(+) patient group, the ratio of RC-DNA/cccDNA
was lower in the cccDNA methylation positive samples than in
the cccDNA methylation negative samples (Guo et al., 2009).
It is therefore possible that, increased cccDNA methylation
correlates with HBeAg clearance possibly via suppressing pre-
C/C transcription, which in turn can lead to suppressed viral
productivity.
The speciﬁc roles of the DNMTs involved in the HBV
methylation processes have not been clearly identiﬁed yet.
Transfection studies reported that DNMT1, DNMT2 and
DNMT3 expression is up-regulated in response to HBV, leading
to viral methylation, decreased HBV gene expression, viral
replication, and host DNA methylation (Vivekanandan et al.,
2008a, 2010; Liu et al., 2009). Co-transfection experiments with
HBV and DNMT3 were shown to increase cccDNA methylation
and to down-regulation of viral protein and pgRNA production
(Vivekanandan et al., 2010).
In addition, to stimulate transcription by modifying
chromatin dynamics HBx protein has been shown to silence
the expression of some genes by increasing the total DNMT
activity of the host. Park et al. (2013) reported that HBx induced
the upregulation of DNMT1, DNMT3A1 and DNMT3A2,
and selectively facilitated the regional hypermethylation of
the promoters of certain tumor suppressor genes through
de novomethylation via DNMT3A1 and DNMT3A2 recruitment
(Vivekanandan et al., 2010). In addition, Zheng and his group
demonstrated that HBx regulated epigenetic modiﬁcations by
its physical interaction with DNMT3A, either by promoting
DNMT3A recruitment to the promoters of some genes, such
as MT1F and IL-4, and thus inducing their hypermethylation
and downregulation, or by preventing DNMT3A recruitment
to speciﬁc genomic loci and thus activating the transcription
of genes, such as CDH6 and IGFBP3 (Zheng et al., 2009).
Fernadez and his group showed that most of the HBV genomes,
although more methylated than the pre-malignant lesions,
retained unmethylated the HBV gp3 gene, which codes for
HBx (Fernandez et al., 2009). A recent study showed that
the HBx protein impairs the expression of urokinase-type
plasminogen (uPA), a serine protease essential for the activation
of the hepatocyte growth factor (HGF) that activates hepatic
regeneration (Park et al., 2013). HBx-induced uPA inhibition
is regulated epigenetically by the hypermethylation of the uPA
promoter (Park et al., 2013). In particular, in HBx-expressing
cells, the CpG region of the uPA promoter was found to be 99.7%
methylated resulting in the hypoactivation of pro-HGF and
eventually hampering liver regeneration (Park et al., 2013).
HBV INTEGRATION AND
HEPATOCARCINOGENESIS
HCC is the third most common cause of cancer globally and
chronic HBV patients have 100-fold greater risk of developing
hepatocellular cancer. Ninety percept of HBV-associated liver
cancers show integration of the HBV genome within the human
genome (Fernandez et al., 2009). The development of HCC in
HBV infection involves two major mechanisms: (1) the viral
integration in the host’s genome causes cis-eﬀects that inactivate
tumor-suppressor genes and activate oncogenes and (2) the
expression of trans-activating HBV proteins, such as the HBx
and the PreS2 activators, which disrupt the signal transduction
pathways and alter the expression of the infected hepatocyte
(Schluter et al., 1994; Park et al., 2013).
Similarly to other oncoviruses (HPV16 and HPV18), the
HBV genome, is almost unmethylated in the early stages
of carcinogenesis while it becomes more methylated in the
established HCC (Fernandez et al., 2009). Hepatitis C virus
(HCV) contributes to carcinogenesis by inducing regional
hypermethylation of CpG islands in the promoter regions
of multiple genes (Calvisi et al., 2007). In HBV-induced
carcinogenesis, HBx can accelerate hepatocarcinogenesis
epigenetically by promoting hypermethylation of tumor
suppressor genes by modulating DNMT1 and DNMT3A
expression (Park et al., 2013). Moreover, HBx was reported to
induce hypermethylation of the E-cathedrin promoter via the
activation of DNMT1 in vitro (Lee et al., 2005). In addition to
DNMT expression, high HBx expression has been correlated
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with the hypermethylation of the promoter of the major tumor
suppressor gene p16INK4A and the subsequent reduction in p16
protein expression in non-cancerous tissue but not in HCC tissue
suggesting that HBx plays an important role in the early stages of
HBV associated HCC (Zhu et al., 2007).
HCC has been associated with high methylation of CpG island
I which overlaps with the HBsAg gene starting site (Kaur et al.,
2010). Another study, conﬁrmed the progressive presence of
hypermethylation at the HBV gp2 locus that encodes for S viral
proteins in primary liver tumors (Fernandez et al., 2009).
HBV EPIGENETIC CONTROL OF HOST’S
IMMUNE RESPONSES
Host DNMT upregulation by viruses can be a non-speciﬁc innate
response to infection. HBV has been shown to induce genome-
wide DNA methylation changes, including immunoregulatory
genes that are active against HBV (Ancey et al., 2015). In
particular, HBV replication was reported to cause the de novo
methylation and decrease of IL4, which beneﬁts the virus since
IL4 expression inhibits HBV replication (Zheng et al., 2009). In
addition, unmethylated CpG dinucleotides have been shown to
trigger toll-like receptors expressed in hepatic cells in vitro, which
in turn can activate the NF-κB pathway that plays a key role
in the innate system’s ability to inhibit HBV replication (Liaw
et al., 2009). Nevertheless, this potentially protective eﬀect of
DNMT upregulation may be oﬀset over time either through viral
manipulation of the host methylation machinery or through non-
speciﬁc methylation of host CpG islands as a result of chronic
over expression of DNMTs. For example, latent viruses, such as
Epstein-Barr virus (EBV), are maintained in their latent state in
part by methylation, suggesting that some viruses have evolved
strategies to manipulate host DNMTs to their advantage. HBV
viral proteins can lead to DNMT upregulation and eventually
to methylation of the host genes, including oncogenes. A recent
study by Tropberger and his group showed that transcription and
active PTMs in cccDNA are reduced by the activation of an innate
pathway, and that this eﬀect can be recapitulated with a small
molecule epigenetic modifying agent (Tropberger et al., 2015).
THERAPEUTIC IMPLICATIONS OF
EPIGENETIC MECHANISMS IN HBV
INFECTION
The most important goal in HBV research is the development
of therapies to eradicate HBV infection. Considering the long
half-life of the hepatocytes, the limiting factor in eliminating
infection is the clearance of the cccDNA pool from the infected
cells. Therefore, interfering with the epigenetic regulation of the
cccDNA minichromosome is the most promising therapeutic
approach. Experiments in humanized mice and cell culture
demonstrated that treatment with IFN-α induces cccDNA-
bound histone hypoacetylation and the active recruitment of
transcriptional co-repressors onto cccDNA (Belloni et al., 2012).
IFN-α administration was also shown to reduce binding of STAT1
and STAT2 transcription factors to active cccDNA (Chen et al.,
2013). Treatment with IFN and other potential cytokines that
can activate the cellular response via the epigenetic modiﬁcations
of cccDNA could mark the episome for selective eradication of
infected cells or prevent cccDNAmolecules from re-entering into
nuclei after mitosis. Epigenetic alterations could also potentially
alter cccDNA partitioning into daughter cells. Exploring the
molecular mechanisms by which IFN-α mediates epigenetic
repression of cccDNA transcriptional activity and identifying
new molecular determinants can lead to the development of a
treatment that would eradicate cccDNA molecules.
In CHB infection, viral and host DNA is a host defence
mechanism to suppress viral replication. Increased expression
of DNMTs has been reported in CHB livers that facilitates
viral genome methylation and aﬀects protein production and
viral replication (Guo et al., 2009; Vivekanandan et al., 2010).
Furthermore, host DNA methylation has been shown to be
the main mechanism inactivating relevant genes in HCC,
suggesting a potential role of strong demethylating agents
in the treatment of HCC (Claus et al., 2005; Tong et al.,
2009). However, such potent demethylating treatment could
lead to the reactivation of HBV replication. Conﬁrming that
methylation of non-integrated HBV genomes can regulate
viral replication and cccDNA transcription leads to several
signiﬁcant clinical correlates. Dietary consideration may
potentially be important in modulating HBV replication, as
dietary deﬁciencies can limit the liver’s ability to methylate
HBV. Mouse experiments showed that dietary supplementation
with folate, vitamin B12, choline and betaine could lead to host
gene methylation (Waterland, 2006). These ﬁndings indicate a
potential role of methylation in the future treatment of CHB
infection.
CONCLUDING REMARKS
In the last decade our knowledge on epigenetic modiﬁcations
in viral infection has increased dramatically. DNA methylation
and histone modiﬁcations have been shown to play important
roles in regulating the expression of a variety of HBV genes and
viral replication. The holy grail of the future of HBV therapy
is the complete elimination of cccDNA of all the infected cells
in the host. The association of the cccDNA acetylation changes
with viral replication and transcription shows that the dynamic
acetylation and deacetylation of cccDNA-associated histones is
essential in cccDNA transcription. Additionally, IFN-α has been
shown to actively decay cccDNA due to acetylation modiﬁcations
but the exactmechanisms and the role of cell division in cytokine-
induced cccDNA elimination remain to be determined. DNA
methylation is also being increasingly recognized to play a role in
regulation of HBV gene expression. Both integrated and episomal
HBV DNA can be methylated in human tissues and high HBV
DNA methylation associates with HCC development. Studies on
cccDNA methylation have provided conﬂicting results mainly
because the content of cccDNA in the infected hepatocytes is
maintained by the de novo cccDNA synthesis and possibly due
to the diﬀerent HBV genotypes and experimental approaches
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applied. HBx has been shown to play a key role in the acetylation
and methylation of cccDNA either directly by being recruited
onto the cccDNA minichromosome and indirectly by the
modulation of epigenetic-associated proteins, including DNMTs
and cccDNA-bound histones. Enhancing our understanding
of the epigenetic consequences of HBV-host interactions will
lead to the identiﬁcation of novel potential therapeutic targets
for selective inhibition of cccDNA transcription and therefore
complete eradication of HBV infection. Since the epigenetic
processes are reversible they would also provide new molecular
determinants by which host and environmental factors can
regulate HBV replication and pathogenesis.
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